Heatwurx (PCSA) to Release Earnings on Thursday

Heatwurx (NASDAQ:PCSA) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Heatwurx to post earnings of ($1.00) per share for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Heatwurx Stock Performance

Shares of PCSA opened at $2.03 on Thursday. The business’s 50-day moving average is $2.29 and its two-hundred day moving average is $2.58. The company has a market capitalization of $5.62 million, a P/E ratio of -0.22 and a beta of 0.99. Heatwurx has a fifty-two week low of $1.67 and a fifty-two week high of $14.24.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heatwurx in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $25.00.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.